Analyst Activity – BTIG Research Initiates Coverage On Axsome Therapeutics (NASDAQ:AXSM) With a Buy

24

Analyst Ratings For Axsome Therapeutics (NASDAQ:AXSM)

Today, BTIG Research initiated coverage on Axsome Therapeutics (NASDAQ:AXSM) with a Buy with a price target of $14.00.

There are 4 buy ratings on the stock.

The current consensus rating on Axsome Therapeutics (NASDAQ:AXSM) is Buy (Score: 3.00) with a consensus target price of $15.67 per share, a potential 282.11% upside.

Some recent analyst ratings include

  • 5/19/2017-BTIG Research initiated coverage with a Buy rating.
  • 3/21/2017-Aegis Reiterated Rating of Buy.
  • 10/3/2016-Brean Capital initiated coverage with a Buy rating.

Dividend information for Axsome Therapeutics (NASDAQ:AXSM)

.
Recent Insider Trading Activity For Axsome Therapeutics (NASDAQ:AXSM)
Axsome Therapeutics (NASDAQ:AXSM) has insider ownership of 42.30% and institutional ownership of 33.07%.

  • On 12/23/2015 Randall Kaye, Insider, bought 1,000 with an average share price of $9.03 per share and the total transaction amounting to $9,030.00. View SEC Filing

About Axsome Therapeutics (NASDAQ:AXSM)
Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain. It is developing AXS 02 for the treatment of pain in over three conditions, such as complex regional pain syndrome (CRPS); knee osteoarthritis (OA) associated with bone marrow lesions (BMLs), and chronic low back pain (CLBP), associated with type I, or mixed type I and type II Modic changes (MCs). Its product candidate, AXS 05, is a fixed dose combination of dextromethorphan (DM) and bupropion. It is developing AXS 05 for the treatment of over two conditions, such as treatment resistant depression (TRD), and agitation in patients with Alzheimer’s disease (AD).

Recent Trading Activity for Axsome Therapeutics (NASDAQ:AXSM)
Shares of Axsome Therapeutics closed the previous trading session at 4.10 up +0.30 7.89% with 733,823 shares trading hands.

An ad to help with our costs